Cargando…
Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells
Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options are limited. Combining venetoclax with immunotherapies is an attractive approa...
Autores principales: | Teh, Charis E., Peng, Hongke, Luo, Meng-Xiao, Tan, Tania, Trussart, Marie, Howson, Lauren J., Chua, Chong Chyn, Muttiah, Christine, Brown, Fiona, Ritchie, Matthew E., Wei, Andrew H., Roberts, Andrew W., Bryant, Vanessa L., Anderson, Mary Ann, Lindeman, Geoffrey J., Huang, David C. S., Thijssen, Rachel, Gray, Daniel H. D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275705/ https://www.ncbi.nlm.nih.gov/pubmed/36521105 http://dx.doi.org/10.1182/bloodadvances.2022008221 |
Ejemplares similares
-
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022) -
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma
por: Phillips, Tycel J., et al.
Publicado: (2023) -
Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study
por: Moreno, Carol, et al.
Publicado: (2023) -
Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active
por: Garcia, Jacqueline S., et al.
Publicado: (2021) -
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
por: Cherry, Evan M., et al.
Publicado: (2021)